Lv7
4320 积分 2022-07-07 加入
Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial
1天前
已完结
Daraxonrasib for Previously Treated RAS-Mutant Non–Small-Cell Lung Cancer
1天前
已完结
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
5天前
已完结
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial
9天前
已完结
Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial
10天前
已完结
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study
11天前
已完结
The landscape for therapeutic cancer vaccines
14天前
已完结
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial
16天前
已完结
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS -Mutated Melanoma
18天前
已完结
Liquid Biopsies for Cancer
19天前
已完结
皖公网安备34019202002308
